The internet has become the new street corner for illicit drug sales, and the latest substance being peddled is the unapproved weight-loss drug retatrutide. According to Peter Pitts, President and Co-founder of the Center for Medicine in the Public Interest, consumers are being deceived into buying this investigational drug from medical spas and online sellers who present it as a safe, clinically tested alternative to approved therapies. However, retatrutide has not received approval from the U.S. Food and Drug Administration (FDA) and cannot be lawfully sold.
Pitts highlights that these illegal sellers are exploiting polished websites and professional packaging to market retatrutide as equivalent or even superior to FDA-approved treatments for obesity. The drug is sourced from unregistered foreign manufacturers, with no assurances of sterility, potency, or ingredient authenticity. This lack of oversight means that when something goes wrong, there is no accountability, and consumers have no way of knowing what they are actually injecting.
The consequences are already evident. Documented reports describe hospitalizations for acute kidney damage and severe gastrointestinal distress. One 42-year-old woman was rushed to the emergency room after experiencing severe symptoms from black market retatrutide purchased online. Poison center reports have surged, with hundreds of cases reported in the first four months of 2026 alone.
The FDA's response has been criticized as woefully inadequate. Pitts argues that issuing a handful of warning letters with no follow-up is "less than a slap on the wrist." Warning letters do not shut down black markets; arrests and seizures do. He emphasizes that the longer this market operates without aggressive enforcement, the more entrenched and normalized it becomes. This inaction sends a message to criminal sellers that there is no risk, leading to even more dangerous schemes.
The deeper threat is institutional. Every day the FDA fails to act, its credibility erodes. Pitts warns that this degradation of institutional authority has consequences that outlast any single drug. Clinical trials exist because consumer demand is not a substitute for scientific evidence. Allowing investigational peptides to become internet lifestyle products before FDA review is not the democratization of medicine but its degradation.
Pitts calls for the FDA to take aggressive steps to shut down this market, coordinating with the Department of Justice, Customs and Border Protection, and the Federal Trade Commission to pursue seizures, injunctions, and criminal referrals against sellers and platforms. He stresses that the longer regulators hesitate, the harder the black market becomes to unwind. The FDA must act now before the window closes to rein in this new frontier for illegal drugs in the digital age.
